These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32088380)

  • 1. Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Ippolito C; Segnani C; Dolfi A; Errede M; Virgintino D; Fornai M; Antonioli L; Garelli F; Nericcio A; Colucci R; Cerri S; Blandini F; Blandizzi C; Bernardini N
    Neurobiol Dis; 2020 Jun; 139():104821. PubMed ID: 32088380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson's disease.
    Levandis G; Balestra B; Siani F; Rizzo V; Ghezzi C; Ambrosi G; Cerri S; Bonizzi A; Vicini R; Vairetti M; Ferrigno A; Pastoris O; Blandini F
    Neurogastroenterol Motil; 2015 Dec; 27(12):1783-95. PubMed ID: 26433214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis.
    Ippolito C; Segnani C; Errede M; Virgintino D; Colucci R; Fornai M; Antonioli L; Blandizzi C; Dolfi A; Bernardini N
    J Cell Mol Med; 2015 Feb; 19(2):485-500. PubMed ID: 25521239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Fornai M; Colucci R; Tirotta E; Blandini F; Levandis G; Cerri S; Segnani C; Ippolito C; Bernardini N; Cseri K; Blandizzi C; Haskó G; Antonioli L
    J Neuroinflammation; 2016 Jun; 13(1):146. PubMed ID: 27295950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
    Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats.
    Zhang X; Li Y; Liu C; Fan R; Wang P; Zheng L; Hong F; Feng X; Zhang Y; Li L; Zhu J
    Transl Res; 2015 Aug; 166(2):152-62. PubMed ID: 25766133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis.
    Ippolito C; Colucci R; Segnani C; Errede M; Girolamo F; Virgintino D; Dolfi A; Tirotta E; Buccianti P; Di Candio G; Campani D; Castagna M; Bassotti G; Villanacci V; Blandizzi C; Bernardini N
    J Crohns Colitis; 2016 Oct; 10(10):1194-204. PubMed ID: 26995183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GDNF's Role in Mitigating Intestinal Reactive Gliosis and Inflammation to Improve Constipation and Depressive Behavior in Rats with Parkinson's disease.
    Xiaoling Q; Yurong G; Ke X; Yuxiang Q; Panpan A; Yinzhen D; Xue L; Tingting L; Chuanxi T
    J Mol Neurosci; 2024 Aug; 74(3):78. PubMed ID: 39158627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Zn
    Tamano H; Nishio R; Morioka H; Takeda A
    Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats.
    Fornai M; Pellegrini C; Antonioli L; Segnani C; Ippolito C; Barocelli E; Ballabeni V; Vegezzi G; Al Harraq Z; Blandini F; Levandis G; Cerri S; Blandizzi C; Bernardini N; Colucci R
    J Pharmacol Exp Ther; 2016 Feb; 356(2):434-44. PubMed ID: 26582732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson's Disease Models.
    Garrido-Gil P; Rodriguez-Perez AI; Dominguez-Meijide A; Guerra MJ; Labandeira-Garcia JL
    Mol Neurobiol; 2018 Sep; 55(9):7297-7316. PubMed ID: 29404956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
    Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
    Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk?
    Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT
    Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central dopaminergic control of cell proliferation in the colonic epithelium.
    Yu S; Peng HR; Zhang YK; Yin YQ; Zhou JW
    Neurosci Res; 2022 Jul; 180():72-82. PubMed ID: 35257836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
    Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
    Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal dysmotility after bowel resection in rats is associated with decreased ghrelin and vimentin expression and loss of intestinal cells of Cajal.
    Sukhotnik I; Ben-Shahar Y; Pollak Y; Cohen S; Moran-Lev H; Koppelmann T; Gorenberg M
    Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G283-G294. PubMed ID: 33325807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nigrostriatal 6-hydroxydopamine lesions increase alpha-synuclein levels and permeability in rat colon.
    Cui H; Elford JD; Alitalo O; Perez-Pardo P; Tampio J; Huttunen KM; Kraneveld A; Forsberg MM; Myöhänen TT; Jalkanen AJ
    Neurobiol Aging; 2023 Sep; 129():62-71. PubMed ID: 37271045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.